New cell therapy offers hope for leukemia patients too sick for chemo
NCT ID NCT07335094
First seen Jan 12, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This early-phase study tests a new treatment for adults with B-cell acute lymphoblastic leukemia or lymphoma who cannot tolerate intensive chemotherapy. Patients receive a single infusion of their own immune cells (CAR-T cells) that have been modified to target cancer cells. The study will monitor safety and how well the treatment works over three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.